Justin Kurian's Colleagues at Prelude Therapeutics
Rachel Chiaverelli
Director, Translational Medicine/Clinical Biomarker Lead
Justin Kurian's Contact Details
(302) 467-1280
Bensalem, Pennsylvania, United States
Prelude Therapeutics
Justin Kurian's Company Details
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways forcancers with selectable underserved patients. Prelude’s pipeline includes three candidates currently in clinical development: PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor, and a preclinical oral candidate targeting SMARCA2.